Russell Investments Group Ltd. Has $7.32 Million Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Russell Investments Group Ltd. increased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 79.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 247,325 shares of the medical device company’s stock after buying an additional 109,505 shares during the quarter. Russell Investments Group Ltd.’s holdings in Tandem Diabetes Care were worth $7,316,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Truist Financial Corp bought a new position in shares of Tandem Diabetes Care in the 4th quarter worth $2,588,000. GAMMA Investing LLC acquired a new position in shares of Tandem Diabetes Care during the fourth quarter valued at about $73,000. Jennison Associates LLC increased its position in shares of Tandem Diabetes Care by 14.9% during the fourth quarter. Jennison Associates LLC now owns 1,290,590 shares of the medical device company’s stock worth $38,176,000 after acquiring an additional 167,675 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Tandem Diabetes Care by 38.3% in the 4th quarter. Handelsbanken Fonder AB now owns 14,800 shares of the medical device company’s stock worth $438,000 after acquiring an additional 4,100 shares during the last quarter. Finally, Signaturefd LLC lifted its position in Tandem Diabetes Care by 871.8% in the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after acquiring an additional 1,517 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Citigroup increased their price objective on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. StockNews.com upgraded Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday, April 19th. Leerink Partnrs upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 25th. SVB Leerink raised shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and raised their price target for the company from $34.00 to $45.00 in a research report on Thursday, April 25th. Finally, Wells Fargo & Company upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $21.00 to $45.00 in a report on Monday, April 29th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.80.

Tandem Diabetes Care Trading Up 1.1 %

NASDAQ:TNDM opened at $44.00 on Wednesday. Tandem Diabetes Care, Inc. has a 12 month low of $13.82 and a 12 month high of $47.00. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43. The firm’s 50 day moving average is $32.91 and its 200 day moving average is $26.53. The stock has a market capitalization of $2.84 billion, a PE ratio of -20.28 and a beta of 1.10.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. Sell-side analysts expect that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.